FOUNDATIONONE®CDx

PATIENT
Chien, Li-Shu

TUMOR TYPE
Nasopharynx and paranasal sinuses undifferentiated carcinoma

COUNTRY CODE
TW

REPORT DATE
05 Oct 2021

ORDERED TEST #
ORD-1194451-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT

DISEASE Nasopharynx and paranasal sinuses undifferentiated carcinoma
NAME Chien, Li-Shu
DATE OF BIRTH 01 December 1966
SEX Female
MEDICAL RECORD # 19906060

PHYSICIAN

ORDERING PHYSICIAN Mu-Hsin Chang, Peter
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN

SPECIMEN SITE Lung
SPECIMEN ID S109-16673C (PF21020)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 05 June 2020
SPECIMEN RECEIVED 28 September 2021

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 0 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

SMARCB1 loss
CHEK2 loss exons 2-10

1 Therapies with Clinical Benefit
0 Therapies with Resistance
18 Clinical Trials

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	**No therapies or clinical trials.** see Biomarker Findings section	
Tumor Mutational Burden - 0 Muts/Mb	**No therapies or clinical trials.** see Biomarker Findings section	
GENOMIC FINDINGS	**THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)**	**THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)**
***SMARCB1* -** loss	none	Tazemetostat
9 Trials *see p. 8*		
***CHEK2* -** loss exons 2-10	none	none
10 Trials *see p. 6*		

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Electronically signed by Erik Williams, M.D. | 05 October 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

MSI-high (MSI-H) has been observed at high frequency in endometrial cancers (14-33%)[6-13], colorectal cancers (CRCs; 10-15%)[3,14-17], and gastric cancers (12-35%)[18-21] and at lower frequencies in many other tumor types, including esophageal[22], small bowel[23-27], hepatobiliary[28-34], prostate[35-37], and urinary tract carcinomas[38-40]. One retrospective study of patients with Stage 2-4a nasopharyngeal carcinoma treated with intensity-modulated radiotherapy in China reported that deficiency of mismatch repair protein expression independently correlated with better distant metastasis-free survival (HR=0.25)[41].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[16]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[16,42-43]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[15,44-45]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[15-16,43,45].

BIOMARKER

Tumor Mutational Burden

RESULT
0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[46-48], anti-PD-1 therapies[46-49], and combination nivolumab and ipilimumab[50-55]. In multiple pan-tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors[46-49,56]. Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors[46].

Analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16-20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy, compared with patients with higher TMB treated with chemotherapy[57] or those with lower TMB treated with PD-1 or PD-L1-targeting agents[47]. However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB ≥10 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials[49,56]. Together, these studies suggest that patients with TMB ≥10 Muts/Mb may derive clinical benefit from PD-1 or PD-L1 inhibitors.

FREQUENCY & PROGNOSIS

Nasopharyngeal and sinonasal undifferentiated carcinoma harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 1.9% of cases have high TMB (>20 muts/Mb)[58]. Published data investigating the prognostic implications of TMB in nasopharyngeal and sinonasal carcinoma are limited (PubMed, Oct 2021).

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[59-60] and cigarette smoke in lung cancer[61-62], treatment with temozolomide-based chemotherapy in glioma[63-64], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[17,65-68], and microsatellite instability (MSI)[17,65,68]. This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types[47-48,56].

Electronically signed by Erik Williams, M.D. | 05 October 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
SMARCB1

ALTERATION
loss

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Clinical and preclinical evidence suggests that tumors with loss of SMARCB1 may be sensitive to a variety of targeted therapies, including EZH2 inhibitors[69-72], CDK4/6 inhibitors[73-76], Aurora kinase inhibitors[77], and anti-PD-1 immune checkpoint inhibitors[78-81]. The EZH2 inhibitor tazemetostat has shown efficacy in adult and pediatric patients with INI1-negative solid tumors across Phase 1 and 2 trials, predominantly in sarcoma subtypes[69]. A clinical trial of the Aurora kinase A inhibitor alisertib for pediatric patients with atypical teratoid rhabdoid tumors, which are characterized by SMARCB1 loss or inactivation, reported disease stabilization or regression in 100% (4/4) of patients, and 2 patients achieved disease regression lasting more than 1 year[82]. A study of INI1-negative pediatric solid tumors observed frequent signs of T-cell inflammation, including PD-L1 expression in 47% (14/30) of patients, and reported 3 patients with metastatic epithelioid sarcoma, anaplastic chordoma, or malignant rhabdoid tumor who experienced disease control on pembrolizumab or nivolumab for at least 12, 9, and 3 months, respectively[78]. Case studies have reported a patient with treatment-refractory metastatic epithelioid sarcoma had a PR on nivolumab plus ipilimumab, with the addition of pazopanib leading to a CR of >12 months[83]; a patient with SMARCB1-mutated metastatic renal medullary carcinoma (RMC) had SD for 7 months with nivolumab[84]; and a patient with metastatic RMC and concurrent SMARCB1 loss and ARID2 mutation had a CR with 9 months of nivolumab treatment[85]. Preclinical evidence also supports PD-1 immune checkpoint blockade as treatment approach for rhabdoid tumors that are characterized by SMARCB1 inactivation and T-cell inflammation[79-80].

FREQUENCY & PROGNOSIS

The loss of SMARCB1 protein expression was reported in 6% of 142 sinonasal carcinomas in another study, with genomic loss of SMARCB1 identified in 75% (6/8) of patients in that subset[86]. In a genomic analysis of 56 nasopharyngeal carcinoma cases, alterations of SMARCB1 was not detected in any of the samples[87]. Loss of SMARCB1 has been reported in all three sinonasal basaloid carcinomas analyzed in one study[88]. In head and neck carcinoma, SMARCB1 inactivation may indicate an INI1-deficient subtype of sinonasal carcinoma characterized by poor differentiation and aggressive clinicopathologic features[86,89].

FINDING SUMMARY

The SMARCB1 gene encodes the SNF5 protein, also known as INI1, one of three core subunits of the SWI/SNF family of chromatin remodeling complexes[90]. SNF5, as a member of the remodeling complex, plays a key role in cell cycle control and can act as a tumor suppressor[91]. Alterations such as seen here may disrupt SMARCB1 function or expression[92-97].

POTENTIAL DIAGNOSTIC IMPLICATIONS

SMARCB1 mutation and loss of protein expression are characteristic of malignant rhabdoid tumors, INI1-deficient sinonasal carcinomas, epithelioid sarcomas, kidney medullary carcinoma and atypical teratoid/rhabdoid tumors, particularly in cases with low TMB and a paucity of co-occurring alterations (NCCN Soft Tissue Sarcoma Guidelines, v2.2021)[78,86,89,98-103].

Electronically signed by Erik Williams, M.D. | 05 October 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
CHEK2

ALTERATION
loss exons 2-10

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Limited clinical data indicate that CHEK2 inactivation may predict sensitivity to PARP inhibitors. Patients with CHEK2-altered prostate cancer have experienced clinical responses to PARP inhibitors[104-106]. Clinical benefit has been observed for patients with ovarian[107] and testicular[108] cancers treated with PARP inhibitors. One study of patients with breast cancer reported that carriers of the CHEK2 H371Y mutation have a higher likelihood of response to neoadjuvant chemotherapy[109], whereas another study found that CHEK2 mutation carriers have a lower frequency of objective clinical responses to neoadjuvant therapy[110]. A third study reported that the CHEK2 1100delC mutation is not associated with differential efficacy of chemotherapy and endocrine therapy in patients with metastatic breast cancer[111].

FREQUENCY & PROGNOSIS

CHEK2 mutations have been reported in 8.3% of glioblastoma (GBM) samples and in carcinomas of the endometrium (3.8%), urinary tract (3.5%), ovary (3.4%), and large intestine (3.1%), and at low frequency in a variety of solid and hematologic cancer types (COSMIC, 2021)[112]. In breast cancer, certain CHEK2 mutations are associated with higher grade and larger tumors as well as bilateral disease[113]. A study reported that a polymorphism in CHEK2 was associated with worse survival of patients with GBM, but this association lost significance after adjusting for other prognostic factors[114-115]. Another study in prostate cancer reported that CHEK2 expression is decreased in higher grade tumors and that CHEK2 is a tumor suppressor that decreases the growth of prostate cancer cells and regulates androgen receptor signaling[116].

FINDING SUMMARY

CHEK2 encodes the protein checkpoint kinase 2, a serine/threonine kinase that plays an important role in the DNA-damage response; it is a putative tumor suppressor[117-120]. Alterations such as seen here may disrupt CHEK2 function or expression[121-131].

POTENTIAL GERMLINE IMPLICATIONS

Germline CHEK2 mutation has been associated with cancer susceptibility of low to moderate penetrance, especially in hereditary breast cancer[132]. CHEK2 germline mutation has been identified in approximately 2.5% of familial or high-risk breast cancer cases[133-134]. Although heterozygous germline CHEK2 mutation increases breast cancer risk two- to three-fold, it is not associated with younger age at diagnosis[134-135]. In the appropriate clinical context, germline testing of CHEK2 is recommended.

Electronically signed by Erik Williams, M.D. | 05 October 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Tazemetostat

Assay findings association

SMARCB1
loss

AREAS OF THERAPEUTIC USE

Tazemetostat is an inhibitor of the histone methyltransferase EZH2. It is FDA approved as a monotherapy for the treatment of metastatic or locally advanced epithelioid sarcoma and relapsed or refractory follicular lymphoma. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of Phase 2 clinical data across sarcoma subtypes and sinonasal carcinoma[70,136-138] , and preclinical evidence[72,139] , loss or inactivation of SMARCB1 may predict sensitivity to tazemetostat.

SUPPORTING DATA

Clinical data on the efficacy of tazemetostat for the treatment of head and neck cancer are limited (PubMed, Aug 2021). In solid tumors, tazemetostat has been primarily investigated in the context of INI1-deficient sarcomas. A Phase 2 study for patients with INI1-negative tumors treated with tazemetostat reported ORRs (all PRs) of 15% (9/62) for the epithelioid sarcoma cohort[136], 0% (0/11) for the malignant rhabdoid tumor (MRT) cohort[140], and 9.4% (3/32) for those with other solid tumors, including PRs in 2 of 13 patients with sarcoma (both spindle cell sarcoma) and 1 of 16 patients with non-mesenchymal tumors (a sinonasal carcinoma)[137]. For patients with synovial sarcoma, a Phase 2 study reported that treatment with tazemetostat monotherapy achieved SD as best response in 33% (11/33) of patients, with 5 SDs lasting ≥16 weeks[141]. Additional Phase 1/2 trials for tazemetostat have reported clinical benefit for adult patients with small cell carcinoma of the ovary, hypercalcemic type (2 PRs)[70,140,142] malignant mesothelioma (2 PRs)[143], and MRT (1 CR)[70]. A Phase 1 trial for 46 pediatric patients with synovial sarcoma or INI1-negative tumors reported clinical benefit in the context of epithelioid sarcoma (1 CR), chordoma (1 CR, 1PR), or atypical teratoid rhabdoid tumor (ATRT, 1 CR) across tazemetostat dosage groups[138].

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
CHEK2

ALTERATION
loss exons 2-10

RATIONALE
On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.

NCT04123366

PHASE 2

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

TARGETS
PARP, PD-1

LOCATIONS: Fukuoka (Japan), Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)

NCT03742895

PHASE 2

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

TARGETS
PARP

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Ryazan (Russian Federation), Darlinghurst (Australia), Moscow (Russian Federation)

NCT02264678

PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California

NCT04635631

PHASE 1

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

TARGETS
PARP

LOCATIONS: Beijing (China), Changchun (China)

NCT03772561

PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

Electronically signed by Erik Williams, M.D. | 05 October 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT02769962

PHASE 1/2

Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

TARGETS
PARP, TOP1

LOCATIONS: Maryland

NCT04497116

PHASE 1/2

Study of RP-3500 in Advanced Solid Tumors

TARGETS
ATR, PARP

LOCATIONS: Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas

NCT03127215

PHASE 2

Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

TARGETS
FUS-DDIT3, PARP

LOCATIONS: Dresden (Germany), München (Germany), Frankfurt (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Stuttgart (Germany), Tuebingen (Germany), Freiburg (Germany)

NCT03297606

PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS
VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO

LOCATIONS: Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)

GENE
SMARCB1

ALTERATION
loss

RATIONALE
On the basis of clinical and preclinical evidence, loss or inactivation of SMARCB1 may be associated with sensitivity to EZH2 inhibitors, CDK4/6 inhibitors, and Aurora kinase inhibitors.

Patients with certain SMARCB1-deficient malignant tumors have benefited from anti-PD-1 immune checkpoint inhibitors.

NCT03099174

PHASE 1

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.

TARGETS
CDK4, CDK6, IGF-1, IGF-2, Aromatase, ER

LOCATIONS: Seoul (Korea, Republic of), Goyang (Korea, Republic of), Aichi, Nagoya (Japan), Kanagawa, Isehara (Japan), Tokyo, Chuo-ku (Japan), Tokyo, Koto-ku (Japan), Chiba, Kashiwa (Japan), Helsinki (Finland), Tampere (Finland), Turku (Finland)

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT04104776

PHASE 1/2

A Study of CPI-0209 in Patients With Advanced Solid Tumors

TARGETS
EZH2, TOP1

LOCATIONS: Washington, Michigan, Ohio, Massachusetts, New Jersey, Texas, Virginia, Georgia

NCT02896335

PHASE 2

Palbociclib In Progressive Brain Metastases

TARGETS
CDK4, CDK6

LOCATIONS: Massachusetts

NCT04555837

PHASE 1/2

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

TARGETS
Aurora kinase A, PD-1

LOCATIONS: Texas

NCT04241835

PHASE 1

A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies

TARGETS
EZH2

LOCATIONS: Józefów (Poland), Poznań (Poland), Bratislava (Slovakia), Edegem (Belgium), Brussels (Belgium), Lille (France), Marseille (France), Bordeaux Cedex (France), Nevada, Illinois

Electronically signed by Erik Williams, M.D. | 05 October 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT03065062

PHASE 1

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

TARGETS
PI3K-alpha, PI3K-gamma, mTORC1, mTORC2, CDK4, CDK6

LOCATIONS: Massachusetts

NCT03454035

PHASE 1

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

TARGETS
MAPK3, MAPK1, CDK4, CDK6

LOCATIONS: North Carolina

NCT02897375

PHASE 1

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

TARGETS
CDK4, CDK6

LOCATIONS: Georgia

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

ABL1
T984M

AKT1
R174H

MSH6
K1358fs*2

SETD2
P190L

SPEN
G1286W

Electronically signed by Erik Williams, M.D. | 05 October 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B)*	*APC*
AR	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*	*BTG2*
BTK	*C11orf30 (EMSY)*	*C17orf39 (GID4)*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*
CCND2	*CCND3*	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*
CDH1	*CDK12*	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FAM46C	*FANCA*	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*
FGF14	*FGF19*	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*
FGFR4	*FH*	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*
GATA4	*GATA6*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3F3A*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11A*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*	*P2RY8*	*PALB2*
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*	*PDGFRA*
PDGFRB	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*	*REL*	*RET*
RICTOR	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*	*SDHD*	*SETD2*
SF3B1	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*	*SNCAIP*	*SOCS1*
SOX2	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*	*STK11*	*SUFU*
SYK	*TBX3*	*TEK*	*TET2*	*TGFBR2*	*TIPARP*	*TNFAIP3*	*TNFRSF14*	*TP53*
TSC1	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*	*VHL*	*WHSC1*	*WT1*	*XPO1*
XRCC2	*ZNF217*	*ZNF703*						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV4*
ETV5	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*	*KMT2A (MLL)*
MSH2	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*	*RAF1*
RARA	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***	*TMPRSS2*

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

Electronically signed by Erik Williams, M.D. | 05 October 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. The MSI-H/MSS designation by FMI F1CDx test is based on genome wide analysis of 95 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines. The threshold for MSI-H/MSS was determined by analytical concordance to comparator assays (IHC and PCR) using uterine, cecum and colorectal cancer FFPE tissue. The clinical validity of the qualitative MSI designation has not been established. For Microsatellite Instability (MSI) results, confirmatory testing using a validated orthogonal method should be considered.
2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics

of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.

3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
4. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
5. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
6. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating

Electronically signed by Erik Williams, M.D. | 05 October 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.0.0

The median exon coverage for this sample is 955x

Electronically signed by Erik Williams, M.D. | 05 October 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808
7. Hampel H, et al. Cancer Res. (2006) pmid: 16885385
8. Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490
9. Kanopienė D, et al. Medicina (Kaunas) (2014) pmid: 25458958
10. Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821
11. Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107
12. Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578
13. Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452
14. Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535
15. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
16. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
17. Nature (2012) pmid: 22810696
18. Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621
19. Wu MS, et al. Cancer Res. (1998) pmid: 9537253
20. dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886
21. Fang WL, et al. Biomed Res Int (2013) pmid: 23555086
22. Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910
23. Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525
24. Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434
25. Planck M, et al. Cancer (2003) pmid: 12627520
26. Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257
27. Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578
28. Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185
29. Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944
30. Suto T, et al. J Surg Oncol (2001) pmid: 11223838
31. Momoi H, et al. J. Hepatol. (2001) pmid: 11580146
32. Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736
33. Moy AP, et al. Virchows Arch. (2015) pmid: 25680569
34. Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221
35. Pritchard CC, et al. Nat Commun (2014) pmid: 25255306
36. Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803
37. Burger M, et al. J. Mol. Med. (2006) pmid: 16924473
38. Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119
39. Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978
40. Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567
41. Chen FM, et al. Sci Rep (2020) pmid: 32546739
42. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
43. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
44. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
45. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
46. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
47. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
48. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
49. Cristescu R, et al. Science (2018) pmid: 30309915
50. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
51. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
52. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
53. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
54. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
55. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
56. Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526
57. Legrand et al., 2018; ASCO Abstract 12000
58. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
59. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
60. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
61. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
62. Rizvi NA, et al. Science (2015) pmid: 25765070
63. Johnson BE, et al. Science (2014) pmid: 24336570
64. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
65. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
66. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
67. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
68. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
69. Gounder M, et al. Lancet Oncol (2020) pmid: 33035459
70. Italiano A, et al. Lancet Oncol. (2018) pmid: 29650362
71. Alimova I, et al. Neuro-oncology (2013) pmid: 23190500
72. Knutson SK, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23620515
73. Alarcon-Vargas D, et al. Oncogene (2006) pmid: 16302003
74. Smith ME, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 21173237
75. Geoerger B, et al. Clin. Cancer Res. (2017) pmid: 28432176
76. Hashizume R, et al. Neuro-oncology (2016) pmid: 27370397
77. Lee S, et al. Cancer Res. (2011) pmid: 21521802
78. Forrest SJ, et al. Clin Cancer Res (2020) pmid: 32122923
79. Leruste A, et al. Cancer Cell (2019) pmid: 31708437
80. Chun HE, et al. Cell Rep (2019) pmid: 31708418
81. Panwalkar P, et al. Neuro Oncol (2020) pmid: 31912158
82. Wetmore C, et al. Neuro-oncology (2015) pmid: 25688119
83. Pecora A, et al. J Immunother () pmid: 32815894
84. Sodji Q, et al. J Immunother Cancer (2017) pmid: 28807004
85. Beckermann KE, et al. J Immunother Cancer (2017) pmid: 28105368
86. Bishop JA, et al. Am. J. Surg. Pathol. (2014) pmid: 25007146
87. Lin DC, et al. Nat. Genet. (2014) pmid: 24952746
88. Agaimy A, et al. Am. J. Surg. Pathol. (2014) pmid: 24832165
89. Kakkar A, et al. Hum. Pathol. (2019) pmid: 30120966
90. Wilson BG, et al. Nat. Rev. Cancer (2011) pmid: 21654818
91. Versteege I, et al. Oncogene (2002) pmid: 12226744
92. Morozov A, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9448295
93. Das S, et al. J. Biol. Chem. (2009) pmid: 19398554
94. Zhang ZK, et al. Mol. Cell. Biol. (2002) pmid: 12138206
95. Valencia AM, et al. Cell (2019) pmid: 31759698
96. Kondelin J, et al. EMBO Mol Med (2018) pmid: 30108113
97. Vries RG, et al. Genes Dev (2005) pmid: 15769941
98. Hollmann TJ, et al. Am. J. Surg. Pathol. (2011) pmid: 21934399
99. Oda Y, et al. Cancer Sci. (2009) pmid: 19076980
100. Hasselblatt M, et al. Genes Chromosomes Cancer (2013) pmid: 23074045
101. Rizzo D, et al. Am. J. Surg. Pathol. (2012) pmid: 22614000
102. Sullivan LM, et al. Mod. Pathol. (2013) pmid: 23060122
103. Arnold MA, et al. Hum. Pathol. (2013) pmid: 23245672
104. Abida W, et al. Clin. Cancer Res. (2020) pmid: 32086346
105. Mateo J, et al. Lancet Oncol. (2019) pmid: 31806540
106. Mateo J, et al. N. Engl. J. Med. (2015) pmid: 26510020
107. Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594
108. Gruber et al., 2019; ASCO Abstract 3006
109. Liu Y, et al. BMC Cancer (2015) pmid: 25884806
110. Pfeifer W, et al. Breast Cancer Res. Treat. (2014) pmid: 25414026
111. Kriege M, et al. J. Cancer Res. Clin. Oncol. (2015) pmid: 25958056
112. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
113. Kilpivaara O, et al. Int. J. Cancer (2005) pmid: 15472904
114. Simon M, et al. Neurosurgery (2006) pmid: 17016233
115. Dong YS, et al. Tumour Biol. (2014) pmid: 24532427
116. Ta HQ, et al. Cancer Res. (2015) pmid: 26573794
117. Tomlinson IP, et al. Mutagenesis (2012) pmid: 22294770
118. Xu HP, et al. Nucleic Acids Res. (1990) pmid: 2205842
119. van der Groep P, et al. Cell Oncol (Dordr) (2011) pmid: 21336636
120. Schutte M, et al. Am. J. Hum. Genet. (2003) pmid: 12610780
121. Xu X, et al. Mol. Cell. Biol. (2002) pmid: 12024051
122. Lee CH, et al. J. Biol. Chem. (2001) pmid: 11390408
123. Schwarz JK, et al. Mol. Cancer Res. (2003) pmid: 12805407
124. Ng CP, et al. J. Biol. Chem. (2004) pmid: 14681223
125. Matsuoka S, et al. Proc. Natl. Acad. Sci. U.S.A. (2000) pmid: 10973490
126. Zhou BB, et al. J. Biol. Chem. (2000) pmid: 10744722
127. Ahn JY, et al. Cancer Res. (2000) pmid: 11085506
128. Melchionna R, et al. Nat. Cell Biol. (2000) pmid: 11025670
129. Yoda A, et al. J. Biol. Chem. (2006) pmid: 16798742
130. Chehab NH, et al. Genes Dev. (2000) pmid: 10673500
131. Lee SB, et al. Cancer Res. (2001) pmid: 11719428
132. Mahdavi M, et al. J Cell Physiol (2019) pmid: 30552672
133. Kleiblová P, et al. Klin Onkol (2019) pmid: 31409080
134. Hauke J, et al. Cancer Med (2018) pmid: 29522266
135. Lu HM, et al. JAMA Oncol (2019) pmid: 30128536
136. Stacchiotti et al., 2019; ASCO Abstract 11003
137. Stacchiotti et al., 2018; ESMO Abstract 1611PD
138. Chi et al., 2017; AACR-NCI-EORTC Abstract A175
139. Kawano S, et al. PLoS ONE (2016) pmid: 27391784
140. Jones et al., 2018; ESMO Abstract 1612PD
141. Schoffski et al., 2017; ASCO Abstract 11057
142. Penebre et al., 2015; EORTC Abstract C87
143. Zauderer et al., 2018; ASCO Abstract 8515

Electronically signed by Erik Williams, M.D. | 05 October 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531